Former FDA commissioner explains why a 'plan B' is needed in places using Oxford vaccine

Former Food and Drug Administration Commissioner Scott Gottlieb told CBS News' Margaret Brennan on Sunday that there needs to be a "plan B" in areas where the COVID-19 vaccine developed by the University of Oxford and AstraZeneca is widely used.
The Oxford-AstraZeneca vaccine has been shown to be quite effective in trials, but early findings suggest a drop in its ability to protect against the so-called South African variant. That's troubling because the vaccine is widely seen as a game-changer due to its lower-cost and easy storage method, making it the most likely to candidate to reach harder-to-access communities around the world, especially in developing nations. If the South African variant eventually becomes the dominant source of infections in those areas, that could put things back at square one.
The problem is, Gottlieb explained, the most logical replacement shot — the Johnson & Johnson candidate (which isn't on the market yet) — may be rendered ineffective in people who have already taken the Oxford vaccine since both rely on adenoviruses to draw an immune response. Gottlieb clarified that the latter point is not proven, but the risk is there until data becomes clear. In that case, he said the answer may be to turn to the vaccines that use mRNA technology, such as those developed by Pfizer and Moderna, instead, but they present significant distribution challenges. Tim O'Donnell
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published